(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 September 2014 (04.09.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/132205 A1

(51) International Patent Classification:
A61K 9/20 (2006.01) *A61K 31/428* (2006.01)
A61K 9/48 (2006.01)

(21) International Application Number:
PCT/IB2014/059270

(22) International Filing Date:
26 February 2014 (26.02.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/770,584 28 February 2013 (28.02.2013) US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and
(71) Applicants *(for US only)*: **ACHOUR, Miloud** [FR/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **FAIRHURST, Robin Alec** [GB/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **GRANDEURY, Arnaud** [FR/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **HATAKEYAMA, Shinji** [JP/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **KOZICZAK-HOLBRO, Magdalena** [PL/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **TUFILLI, Nicola** [IT/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **ULLRICH, Thomas** [AT/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH).

(74) Common Representative: **NOVARTIS AG**; Lichtstrasse 35, CH-4056 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2014/132205 A1

(54) Title: FORMULATION COMPRISING BENZOTHIAZOLONE COMPOUND

(57) Abstract: The present invention relates to a pharmaceutical composition in solid oral dosage form comprising (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5- hydroxybenzo[d]thiazol-2(3H)-one acetate salt.